National and Kapodistrian University of Athens
Η φυσική ιστορία της ηπατίτιδας C σε ομάδα αιμορροφιλικών ασθενών
Abstract
dc:descriptionChronic hepatitis C (CHC) is a common cause of morbidity and mortality among haemophiliacs. Coinfection with HIV, almost at the same time point, aggravates the course of HCV infection to ESLD and HCC. Aim of this study was to evaluate the natural history of HCV infection in a cohort of Greek haemophilia patients and investigate the impact of HIV infection in HCV progression. A total of 324 haemophilia patients with CHC and known seroconversion dates were followed up prospectively, among them 160 (49,4%) coinfected with HIV. The cumulative incidence of ESLD and death without ESLD was estimated using competing risks methodology. In coinfected patients, the relative importance of several virological and epidemiological factors in the histologically determined severity of CHC was investigated. The Cox proportional hazards model was used to investigate factors’ effects on the cause-specific hazards of both endpoints. Finally the response to different anti-HCV regimen was evaluated in both groups. The estimated cumulative incidence (95% CI) of ESLD at 30 years was 12%. (4,2%, 15,8%) In total, 34 (10.5%) patients progressed to ESLD, 22 of them among the coinfected. HIV infection was a strong determinant of negative outcome. Cumulative incidence of ESLD was higher in HCV/HIC coinfected than in HCV monoinfected patients irrespectively of the years passed from HCV seroconversion. HCC was diagnosed in 1,9% of the patients, exclusively in the ΖIV negative group. In liver histology a significant positive association of hepatitis grade with CD4 level was observed, suggesting that coinfection may aggravate the course of hepatitis, most probably through an immune mediated process. The impact of HAART in coinfected patients had beneficial effect in HCV infection course. While a mild transient hepatotoxicity was observed during the first months after HAART initiation, immune recovery resulted in significant reduction (81,9%) of cause specific hazard for ESLD (p=0.001). In fact, there was no statistically significant difference in CSH of ESLD between monoinfected individuals and HCV/HIV coinfected patients with stable HAART (p-value=0.413). Treatment for HCV infection was found to be safe and effective in HIV negative patients, with response rates similar to other HCV positive groups, in contrast to coinfected patients, where, very low response rate and high incidence of adverse events was found. Conclusions: Greek Haemophilia patients present a high incidence of HCV infection and CHC. The cumulative incidence of ESLD 30 years after HCV infection is relatively low, but higher among coinfected patients. An early and potent anti-HIV therapy in this group or patients, before the occurrence of immunosuppression, may reduce the rate of HCV morbidity and mortality. Anti-HCV therapy has similar safety and response rate to other risk groups only in monoinfected patients.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2013
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Katsarou, Olga
- Κατσαρού, Όλγα
Subjects
dc:subject × 10Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/39763